Adult Immunization

Infectious disease expert Amesh Adalja, MD, discusses new vaccine policies, misinformation, and how PCPs can build confidence during National Immunization Awareness Month.

A recent poll reveals most US adults are hesitant about fall COVID-19 vaccinations, highlighting confusion over federal policies and declining trust in health agencies.

Schaffner describes the mood among his colleagues in infectious disease right now as anxious, perplexed, distressed, and angry. They expect the disruptions and their feelings to continue.

Infectious disease physician Amesh Adalja, MD, explains how PCPs can reframe vaccines as health technology to boost confidence and counter hesitancy.

Amesh Adalja, MD, explains how physicians can rebut social media vaccine claims with concise, referenced facts and patient-centered communication.

Dr Adalja offers evidence-based strategies to address patient concerns about aluminum and thimerosal in vaccines.

The prefilled syringe presentation streamlines administration of the vaccine, eliminating the need to combine the lyophylized antigen and separate adjuvant.

GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.

The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?

CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.

The vaccine showed superior relative vaccine efficacy that was 26.6% higher than a licensed standard-dose influenza vaccine, Moderna reported.

FDA panel endorses continued use of monovalent JN.1 strain for COVID-19 vaccines, aligning with global health recommendations amid evolving variants.

Moderna voluntarily withdrew the BLA after consultation with the FDA and will resubmit once it has additional phase 3 efficacy data for its investigational flu shot.

Your daily dose of the clinical news you may have missed.

Nuvaxovid (NVX-CoV2373) is indicated for those aged ≥65 years and aged 12 to 64 years with at least one condition that puts them at high risk for severe infection.

Cases of whooping cough in the US more than doubled in 2024, and 2 infants have died from the infection. Here is background on the infection and vaccine.

Misinformation about measles and the MMR vaccine has reached the majority of US adults and parents; most believe the vaccine is safe but many are still unconvinced.

Novavax’s COVID-19 vaccine was linked to fewer and less severe side effects vs mRNA in a University of Utah study of health care workers.

Respiratory syncytial virus was deadly and untreatable across the lifespan until 2023 when the first vaccines were approved in the US. Follow the timeline, here.

As the US measles outbreak tops 600 cases, Texas reported a second child's death in a young girl who was unvaccinated and had no underlying health conditions.

The FDA granted fast track designation to Sanofi’s chlamydia vaccine candidate today, aiming to prevent infections and address an unmet public health need.

CROI 2025: Increased HPV vaccine coverage could reduce HIV cases by thousands, according to a new study.

Get the latest immunization updates, data on racial disparities, and practical guidance for clinical practice, here.

Your daily dose of the clinical news you may have missed.

The Metrix COVID/Flu molecular test detects and differentiates SARS-CoV-2, influenza A, and influenza B in approximately 20 minutes.

The ACIP of the CDC will meet on February 26 to vote on recommendations for appropriate incorporation of Penmenvy into the routine vaccination schedule.

People with chronic diseases like COPD or with immunocompromising conditions continue to have reservations about vaccines against flu, COVID-19, and RSV.

The novel therapeutic demonstrated a strong safety profile and showed efficacy in reducing symptoms during the early stages of treatment.

The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.

Robert Hopkins, Jr, MD, NFID medical director, details a range of resources on the foundation's website including in-depth vaccine recommendations, live webinars, plus much more.